NCT01220466已完成不适用
A Prospective Study to Evaluate the Performance and Acceptability of the iDesign Advanced WaveScan Study(tm) System
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 4
- 主要终点
- Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better.
研究概览
简要总结
The results of this trial will demonstrate that the iDesign System performs as intended and is acceptable in a clinical setting.
详细描述
LASIK treatment across the range of myopia with or without astigmatism, hyperopia with or without astigmatism, and mixed astigmatism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, of any race, and at least 18 years old at the time the consent form is signed.
- •The refractive error, based on manifest refraction (adjusted for optical infinity), must be MRSE up to -15.00 D with manifest cylinder between 0.00 and -6.00 D; MRSE up to +9.00 D with cylinder between 0.00 and +6.00 D; or manifest cylinder (from 1.00 to 6.00 D) greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.
- •BSCVA of 20/20 or better.
- •Myopes must be 20/40 or worse.
- •Subjects with Hyperopia or mixed astigmatism, treatment may be based on difficulty maintaining UCVA of 20/40 evidenced by spectacle/contact lens dependence for distance, as documented by the investigator.
- •Wavefront diameter ≥ 4.0 mm.
- •Sufficient agreement between manifest refraction (adjusted for optical infinity) and iDesign System refraction (sphere, cylinder, and axis) to allow treatment selection and generation of an ablation profile as determined by the investigational iDesign System software.
- •Manifest refraction sphere within ± 0.75 D of cycloplegic refraction sphere.
- •Anticipated post-operative stromal bed thickness of at least 250 microns, based on pre-operative central corneal pachymetry minus the maximum treatment depth to be ablated (as calculated by the iDesign System) and the intended flap thickness.
- •Anticipated post-operative keratometry value (based on pre-operative iDesign System refraction and keratometry) that is appropriate.
- •A stable refractive error (based on a previous exam, medical records, or prescription) as compared to the unadjusted pre-operative manifest refraction.
- •Subjects who currently wear contact lenses must demonstrate refractive stability in the operative eye. Rigid or toric lenses must be removed for at least 2 weeks and SCL for at least 3 days prior to the first refraction used to establish stability. A second refraction with a change of no more than ± 0.50 D MRSE at least 7 days after baseline.
- •Willing and capable of returning for follow-up examinations for the duration of the study.
排除标准
- •Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study, as determined by verbal inquiry, or another condition associated with the fluctuation of hormones that could lead to refractive changes.
- •Subjects with an ametropic or amblyopic fellow eye not meeting all inclusion criteria that does not fall within the indications for treatment using the VISX® STAR S4 IR™ Excimer Laser.
- •Concurrent use of systemic (including inhaled) medications that may impair healing, including but not limited to: steroids, antimetabolites, isotretinoin (Accutane™) within 6 months of treatment, and amiodarone hydrochloride (Cordarone™) within 12 months of treatment.
- •Acute or chronic disease, illness, or treatment that would increase the operative risk (e.g., immuno-compromised, autoimmune disease, connective tissue disease, clinically significant atopic disease, diabetes, etc.).
- •Subjects with a cardiac pacemaker, implanted defibrillator, implanted neurostimulator, or any active electrical implants.
- •Ocular condition (other than high myopia) that may predispose the subject to future complications, such as history or evidence of active or inactive corneal disease
- •Previous intraocular or corneal surgery that might confound the outcome of the study or increase risk to the subject.
- •Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
- •Concurrent participation in any other clinical study.
研究组 & 干预措施
Refractive Error
Experimental
干预措施: STAR S4IR LASIK with iDesign Aberrometer (Device)
结局指标
主要结局
Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better.
时间窗: 6 months
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Performance and Acceptability of VSS-RRefractive ErrorNCT01067716Abbott Medical Optics150
终止
不适用
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)CISBladder CancerNCT01314664Endo Pharmaceuticals15
招募中
不适用
Proeftuin Integrative MedicinePatients with chronic musculoskeletal pain, (Osteo)arthritis, rheumatoid arthritis, fibromyalgia, low back pain, neck pain, tennis elbow or golfers arm, non-specific joint complaints, reuma, artrose, fibromyalgie, klachten bewegingsapparaatNL-OMON27322268
已完成
不适用
Development and evaluation of application to improve non-motor symptoms of people with Parkinson's Disease: a pilot studyDiseases of the nervous systemKCT0005196Yonsei University22
已完成
不适用
Feasibility of M-health Version of "What Were We Thinking" Intervention to Promote Maternal Postpartum Mental HealthAnxiety Disorders and SymptomsMaternal BehaviorDepression, PostpartumNCT04847076Universidad del Desarrollo128